<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04180488</url>
  </required_header>
  <id_info>
    <org_study_id>EFC16461</org_study_id>
    <secondary_id>2019-003775-19</secondary_id>
    <secondary_id>U1111-1241-8208</secondary_id>
    <nct_id>NCT04180488</nct_id>
  </id_info>
  <brief_title>Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab</brief_title>
  <acronym>CUPID</acronym>
  <official_title>Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naïve to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To demonstrate the efficacy of dupilumab in study participants with CSU who remain&#xD;
      symptomatic despite the use of H1 antihistamine (Study A: omalizumab naïve; Study B:&#xD;
      omalizumab intolerant or incomplete responders)&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To demonstrate the efficacy of dupilumab on urticaria activity composite endpoint and itch or&#xD;
      hives, separately, at various timepoints To demonstrate the efficacy of dupilumab on&#xD;
      angioedema To demonstrate the efficacy of dupilumab on urticaria control To demonstrate&#xD;
      improvement in health-related quality of life and overall disease status and severity To&#xD;
      evaluate the ability of dupilumab in reducing the proportion of patients who require&#xD;
      treatment with oral corticosteroids (OCS) To evaluate safety outcome measures To evaluate&#xD;
      immunogenicity of dupilumab&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of study for each participant will include 2-4 weeks of screening period, 24&#xD;
      weeks of treatment period and 12 weeks of post treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 11, 2019</start_date>
  <completion_date type="Anticipated">June 27, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in weekly itch severity score (except EU and EU reference countries)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change from baseline in weekly itch severity score (ISS7) at Week 24.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>For EU and EU reference countries only: change from baseline in weekly urticaria activity score</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change from baseline in weekly urticaria activity score (UAS7, composite patient reported itch and hive score) at Week 24.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weekly urticaria activity score</measure>
    <time_frame>Baseline to Week 12 and Week 24</time_frame>
    <description>Change from baseline in weekly urticaria activity score (UAS7, composite patient reported itch and hive score) at Week 12 and Week 24 (except EU and EU reference countries).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ISS7</measure>
    <time_frame>Baseline to Week 12 and Week 24</time_frame>
    <description>Change from baseline in ISS7 at Week 12 and Week 24 (in EU and EU reference countries).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weekly hives severity score</measure>
    <time_frame>Baseline to Week 12 and Week 24</time_frame>
    <description>Change from baseline in weekly hives severity score (HSS7) at Week 12 and Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4. Time to ISS7 minimally important (MID) (ISS7 ≥5) response</measure>
    <time_frame>4. Baseline over time until Week 24</time_frame>
    <description>4. Time to ISS7 minimally important (MID) (ISS7 ≥5) response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of ISS7 MID (≥5 points) responders</measure>
    <time_frame>Week 12 and Week 24</time_frame>
    <description>Proportion of ISS7 MID (≥5 points) responders at Week 12 and Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ISS7 at all time points</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change from baseline in ISS7 at all time points (onset of action is assessed by the first p&lt;0.05 that remains significant at subsequent measures until Week 24).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with UAS7 ≤6</measure>
    <time_frame>Week 12 and Week 24</time_frame>
    <description>Proportion of patients with UAS7 ≤6 at Week 12 and Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with UAS7=0</measure>
    <time_frame>Week 12 and Week 24</time_frame>
    <description>Proportion of patients with UAS7=0 at Week 12 and Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in angioedema activity score over 7 days (AAS7)</measure>
    <time_frame>Baseline to Week 12 and Week 24</time_frame>
    <description>Change from baseline in angioedema activity score over 7 days (AAS7) at Week 12 and Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in urticaria control test (UCT)</measure>
    <time_frame>Baseline to Week 12 and Week 24</time_frame>
    <description>Change from baseline in urticaria control test (UCT) at Week 12 and Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of well controlled patients (UCT ≥12)</measure>
    <time_frame>Week 12 and Week 24</time_frame>
    <description>Proportion of well controlled patients (UCT ≥12) at Week 12 and Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in health-related quality-of-life - DLQI</measure>
    <time_frame>Baseline to Week 12 and Week 24</time_frame>
    <description>Change from baseline in health-related quality-of-life (HRQoL) as measured by Dermatology Life Quality Index (DLQI) in patients ≥16 years old.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in health-related quality-of-life - CDLQI</measure>
    <time_frame>Baseline to Week 12 and Week 24</time_frame>
    <description>Change from baseline in health-related quality-of-life (HRQoL) as measured by Children's Dermatology Life Quality Index (CDLQI) in patients ≥6 - &lt;16 years old at Week 12 and Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment of Change (PGIC) of CSU</measure>
    <time_frame>Week 12 and Week 24</time_frame>
    <description>Patient Global Assessment of Change (PGIC) of CSU at Week 12 and Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Patient Global Impression of Severity (PGIS) of CSU</measure>
    <time_frame>Baseline to Week 12 and Week 24</time_frame>
    <description>Change from baseline in Patient Global Impression of Severity (PGIS) of CSU at Week 12 and Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients receiving OCS for CSU during the planned treatment period</measure>
    <time_frame>Baseline over time to Week 24</time_frame>
    <description>Proportion of patients receiving OCS for CSU during the planned treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to event of patients receiving OCS for CSU during the planned treatment period</measure>
    <time_frame>Baseline over time to Week 24</time_frame>
    <description>Tme to event of patients receiving OCS for CSU during the planned treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants experiencing treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Percentage of participants experiencing treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent ADA against dupilumab over time</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Incidence of treatment-emergent ADA against dupilumab over time.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">246</enrollment>
  <condition>Chronic Spontaneous Urticaria</condition>
  <arm_group>
    <arm_group_label>Study A Dupilumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose regimens, on top of non-sedating H1-antihistamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study A Matched Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo, on top of non-sedating H1-antihistamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study B Dupilumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose regimens, on top of non-sedating H1-antihistamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study B Matched Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo, on top of non-sedating H1-antihistamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab SAR231893</intervention_name>
    <description>Pharmaceutical form:Injection solution Route of administration: Subcutaneous</description>
    <arm_group_label>Study A Dupilumab</arm_group_label>
    <arm_group_label>Study B Dupilumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form:Injection solution Route of administration: Subcutaneous</description>
    <arm_group_label>Study A Matched Placebo</arm_group_label>
    <arm_group_label>Study B Matched Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>non sedating H1-antihistamine</intervention_name>
    <description>Pharmaceutical form:Tablet Route of administration: oral administration</description>
    <arm_group_label>Study A Dupilumab</arm_group_label>
    <arm_group_label>Study A Matched Placebo</arm_group_label>
    <arm_group_label>Study B Dupilumab</arm_group_label>
    <arm_group_label>Study B Matched Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Study A: Participant must be ≥6 years to 80 years of age at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  Study B: Participant must be ≥12 years (or the minimum legal age for adolescents in&#xD;
             the country of the investigational site) to 80 years of age at the time of signing the&#xD;
             informed consent&#xD;
&#xD;
          -  Participants who have a diagnosis of CSU refractory to H1 antihistamines (H1-AH) at&#xD;
             the time of randomization defined by&#xD;
&#xD;
          -  Diagnosis of CSU&gt;6 months prior to screening visit&#xD;
&#xD;
          -  Presence of itch and hives for &gt;6 consecutive weeks at any time prior to screening&#xD;
             visit despite the use of H1-AH during this time period&#xD;
&#xD;
          -  Using a study defined H1-antihistamine for CSU treatment&#xD;
&#xD;
          -  During the 7 days before randomization:&#xD;
&#xD;
        UAS7≥16 ISS7≥ 8&#xD;
&#xD;
        o Study A: omalizumab naïve, Study B; intolerant or incomplete responder to omalizumab&#xD;
        Participants must be willing and able to complete a daily symptom e-Diary for the duration&#xD;
        of the study&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Participants are excluded from any of the studies if any of the following criteria apply:&#xD;
&#xD;
          -  Weight is less than 30 kg in adults and adolescents and 15 kg in children aged 6&#xD;
             to&lt;12years&#xD;
&#xD;
          -  Clearly defined underlying etiology for chronic urticarias other than CSU&#xD;
&#xD;
          -  Presence of skin morbidities other than CSU that may interfere with the assessment of&#xD;
             the study outcomes&#xD;
&#xD;
          -  Active atopic dermatitis&#xD;
&#xD;
          -  Severe concomitant illness(es) that, in the investigator's judgment, would adversely&#xD;
             affect the patient's participation in the study&#xD;
&#xD;
          -  Active tuberculosis or non-tuberculous mycobacterial infection, or a history of&#xD;
             incompletely treated tuberculosis unless documented adequately treated.&#xD;
&#xD;
          -  Diagnosed active endoparasitic infections; suspected or high risk of endoparasitic&#xD;
             infection&#xD;
&#xD;
          -  Active chronic or acute infection requiring treatment with systemic antibiotics,&#xD;
             antivirals, antiprotozoals, or antifungals within 2 weeks before the screening visit&#xD;
             and during the screening period&#xD;
&#xD;
          -  Known or suspected immunodeficiency&#xD;
&#xD;
          -  Active malignancy or history of malignancy within 5 years before the baseline visit,&#xD;
             except completely treated in situ carcinoma of the cervix, completely treated and&#xD;
             resolved non-metastatic squamous or basal cell carcinoma of the skin&#xD;
&#xD;
          -  History of systemic hypersensitivity or anaphylaxis to omalizumab or any biologic&#xD;
             therapy, including any excipients&#xD;
&#xD;
          -  Participation in prior dupilumab clinical study, or have been treated with&#xD;
             commercially available dupilumab.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number :8400019</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400017</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400001</name>
      <address>
        <city>Sweetwater</city>
        <state>Florida</state>
        <zip>33172</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400006</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400018</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400020</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400016</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400009</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400008</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400010</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400014</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400015</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400011</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400003</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400007</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0320008</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1023AAB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0320004</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1414AIF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0320006</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0320007</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000BRH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0320005</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000JKR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0320003</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucumán</state>
        <zip>T4000AXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :0320001</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1121ABE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1240009</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T1Y 0B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1240010</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1240008</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1240005</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3B 3S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1240002</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1240007</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 2G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1240006</name>
      <address>
        <city>Trois-Rivieres</city>
        <state>Quebec</state>
        <zip>G8T 7A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1240004</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1560004</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1560001</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1560007</name>
      <address>
        <city>Guangzhou</city>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1560002</name>
      <address>
        <city>Hangzhou</city>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1560008</name>
      <address>
        <city>Hangzhou</city>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1560006</name>
      <address>
        <city>Jinan</city>
        <zip>250013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1560003</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1560005</name>
      <address>
        <city>Wuxi</city>
        <zip>214002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2500001</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2500002</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2500004</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2500003</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2500006</name>
      <address>
        <city>Paris cedex 20</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2500005</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2760001</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2760003</name>
      <address>
        <city>Buxtehude</city>
        <zip>21614</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2760006</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2760007</name>
      <address>
        <city>Kiel</city>
        <zip>24148</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2760005</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3480005</name>
      <address>
        <city>Debrecen</city>
        <zip>4026</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3480004</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3480003</name>
      <address>
        <city>Szolnok</city>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3480002</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920005</name>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima</state>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920009</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>060-0807</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920002</name>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920008</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>236-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920003</name>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920007</name>
      <address>
        <city>Izumo-shi</city>
        <state>Shimane</state>
        <zip>693-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920006</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920001</name>
      <address>
        <city>Shinagawa-Ku</city>
        <state>Tokyo</state>
        <zip>141-8625</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920010</name>
      <address>
        <city>Tachikawa-shi</city>
        <state>Tokyo</state>
        <zip>190-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920004</name>
      <address>
        <city>Nagoya-shi</city>
        <zip>454-8509</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6430008</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454048</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6430006</name>
      <address>
        <city>Kazan</city>
        <zip>420064</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6430007</name>
      <address>
        <city>Krasnodar</city>
        <zip>350020</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6430005</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6430010</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6430002</name>
      <address>
        <city>Moscow</city>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6430009</name>
      <address>
        <city>Saratov</city>
        <zip>410026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6430004</name>
      <address>
        <city>Smolensk</city>
        <zip>214006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6430003</name>
      <address>
        <city>St-Petersburg</city>
        <zip>193231</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6430001</name>
      <address>
        <city>Stavropol</city>
        <zip>355030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240003</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240008</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240005</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Las Palmas</state>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240007</name>
      <address>
        <city>Madrid</city>
        <state>Madrid, Comunidad De</state>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240001</name>
      <address>
        <city>Madrid</city>
        <state>Madrid, Comunidad De</state>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240002</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240004</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240006</name>
      <address>
        <city>Madrid Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240009</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8260002</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8260001</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ,</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8260004</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE4 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 25, 2021</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>November 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2019</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
    <mesh_term>Chronic Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histamine Antagonists</mesh_term>
    <mesh_term>Histamine H1 Antagonists</mesh_term>
    <mesh_term>Histamine H1 Antagonists, Non-Sedating</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

